Kare Chemical Technologies develops catalytic processes for the commercial production of cannabinoids as active pharmaceutical ingredients. They are developing both naturally occurring and novel cannabinoids for pharmaceutical applications. This allows for efficient and scalable manufacturing of cannabinoid-based pharmaceuticals.
Funding
Funding not disclosed
Founders
Product
Problem
The traditional extraction of cannabinoids from plants faces challenges in supply stability, quality control, and scalability, hindering the consistent production of high-purity compounds for pharmaceutical applications. Furthermore, obtaining rare cannabinoids through plant extraction is often inefficient and costly.
Solution
Kare Chemical Technologies develops and commercializes catalytic processes for the synthesis of high-purity cannabinoids, offering a consistent and scalable alternative to plant-derived extraction. Their high-throughput catalyst technologies enable the production of both major and minor cannabinoids, chemically identical to their plant-derived counterparts, with improved control over quality and supply. By using proprietary precursors and catalytic methods, Kare Chemical Technologies facilitates the efficient manufacturing of pharmaceutical-grade cannabinoids, including rare and novel compounds.
Target Audience
The primary target audience includes pharmaceutical companies, cannabinoid-based drug developers, and researchers requiring a reliable and scalable source of high-purity cannabinoids.
Features
- Catalytic synthesis of cannabinoids, ensuring high purity and consistent quality
- Production of major cannabinoids like CBD and THC, as well as minor and rare cannabinoids
- Scalable processes suitable for commercial production of pharmaceutical-grade cannabinoids
- Use of proprietary precursors to enable efficient and controlled synthesis
- Capability to produce deuterated and carbon-13 labeled cannabinoids
- Technology transfer services for implementing their catalytic processes